Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab versus intravenous bisphosphonates in young children with osteogenesis imperfecta
NL-OMON58816Phase 3Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of setrusumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Annualized rate of all radiographically confirmed fractures including morphometric vertebral fractures. Started Jan 2024; status: active, not recruiting.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NL-OMON58816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58816.